Printer Friendly

Unraveling the complexities of depression.

CME learning objectives are to:

* Increase awareness of the prevalence and impact of depression in the primary care patient population

* Recognize common medical illnesses comorbid to depression

* Understand the importance of treating comorbid conditions

* Improve early and accurate detection of depression in at-risk populations

* Develop an understanding of neurotransmitters and their roles in depression

* Define critical considerations guiding treatment

* Identify common patient types to improve clinical decisions

* Improve clinical outcomes

* Recognize the practical application of rescreening tools and patient tracking to increase remission rates

* Use a screening and patient tracking tool via an exam room door chart

Program release: December 1, 2003

Program expiration: November 30, 2004

Program completion time: Based upon trials, the estimated time to complete this program is 5 hours.

Acknowledgment: This supplement was made possible by an unrestricted educational grant from GlaxoSmithKline.

Physician accreditation: This activity has been planned and implemented in accordance with the Accreditation Council for Continuing Medical Education's (ACCME), Standards for Interpreting the Essentials as Applied to Continuing Medical Education Enduring Materials through the joint sponsorship of Michigan State University College of Human Medicine and MediMax Communications Inc. The Michigan State University College of Human Medicine is accredited by the ACCME to sponsor continuing medical education for physicians. Michigan State University adheres to all ACCME standards regarding industry support of continuing medical education for physicians and takes responsibility for the content, quality, and scientific integrity of this CME activity.

Credit designation: The College of Human Medicine at Michigan State University designates this educational activity for a maximum of 5 hours in category I credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Acknowledgment: This CME activity is supported by an unrestricted educational grant from GlaxoSmithKline. The opinions expressed herein are those of the authors and do not necessarily represent the views of the College of Human Medicine at Michigan State University or GlaxoSmithKline.

Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

Disclosure polity: The faculty disclosure policy of Michigan State University College of Human Medicine requires that the authors participating in a CME activity disclose to the audience any relationship with a pharmaceutical company that might pose a potential, apparent, or real conflict of interest with regard to their contribution to the activity, and any discussion of unlabeled or investigational use of any commercial product or devise not yet approved in the United States.

Dr Ashton has received grants/research support from Forest and GlaxoSmithKline. Dr Ashton also serves as a consultant to Eli Lilly and Co, Forest Pharmaceuticals Inc, GlaxoSmithKline, and Pfizer Inc, and serves on the speakers bureaus of Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb Co, Eli Lilly and Co, Forest Pharmaceuticals Inc, GlaxoSmithKline, Janssen Pharmaceutica, Organon, Pfizer Inc, Solvay Pharmaceuticals Inc, and Wyeth Pharmaceuticals. Dr D'Mello serves on the speakers bureaus of AstraZeneca, Janssen Pharmaceutica, Novartis Pharmaceuticals Corp, and Pfizer Inc. Dr Dantz has received grants/research support from Abbott Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, and Wyeth Pharmaceuticals. He also serves as a consultant to GlaxoSmithKline and Janssen Pharmaceutica and serves on the speakers bureaus of Eli Lilly and Co, Janssen Pharmaceutica, Pfizer Inc, and Wyeth Pharmaceuticals. Dr Hefner indicates that she has no relationships to disclose. Dr Leon serves as a consultant to GlaxoSmithKline. Dr Matson indicates that he has no relationships to disclose. Dr Montano serves as a consultant to Eli Lilly and Co, Forest Pharmaceuticals Inc, GlaxoSmithKline, Organon, and Wyeth Pharmaceuticals. Dr Pradko serves as a consultant to GlaxoSmithKline and serves on the speakers bureaus of GlaxoSmithKline, Organon, Pfizer Inc, Solvay Pharmaceuticals Inc, and Wyeth Pharmaceuticals. Dr Sussman has received grants/research support from Bristol-Meyers Squibb Co, GlaxoSmithKline, and Pfizer Inc. Dr Sussman serves as a consultant to Forest Pharmaceuticals, GlaxoSmithKline, Pfizer Inc, VCB Pharma Research Center, and Wyeth Pharmaceuticals and serves on the speakers' bureaus of Forest Pharmaceuticals, GlaxoSmithKline, Novartis Pharmaceuticals Corp, Organon, Ortho McNeil Pharmaceuticals Inc, and Wyeth Pharmaceuticals. Dr Winsberg indicates that he has no relationships to disclose.

The opinions expressed in this supplement are those of the authors and not of the editor or publisher of The Journal of Family Practice. Levels of evidence are explicitly stated.
COPYRIGHT 2003 Quadrant Healthcom, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Journal of Family Practice
Geographic Code:1USA
Date:Dec 1, 2003
Words:716
Previous Article:Should we screen for ovarian cancer?
Next Article:Letter of introduction.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |